The Challenge of ‘Cold’ Tumors and the STING Pathway

Glioblastoma tumors are often described as “cold tumors” – meaning they don’t naturally trigger the body’s immune response. Unlike “hot tumors” which readily attract immune cells, glioblastomas effectively evade detection, hindering the effectiveness of conventional immunotherapies. Researchers have been exploring ways to awaken the immune system against these tumors by stimulating the STING (stimulator of interferon genes) pathway. When a cell detects foreign DNA, the STING pathway activates the immune system, initiating an anti-tumor response.

Previous attempts to activate STING in glioblastoma have shown promise, but the drugs used degrade quickly and require direct injection into the tumor – a highly invasive and often impractical approach for repeated treatments. “We really wanted to minimize patients having to go through that when they are already ill,” explains Akanksha Mahajan, a postdoctoral research associate and first author of the study. “And I thought that we could use the spherical nucleic acid platforms to deliver these drugs in a noninvasive way.”

Spherical Nucleic Acids: A Novel Delivery System

The research team, led by Alexander H. Stegh and in collaboration with Chad A. Mirkin, harnessed the power of spherical nucleic acids (SNAs). Invented by Mirkin, SNAs are nanoscale structures featuring a dense arrangement of DNA or RNA around a central nanoparticle core. These structures have demonstrated superior therapeutic potency compared to traditional drug delivery methods. The team engineered SNAs with gold cores and DNA snippets designed to activate the STING pathway within specific immune cells.

To deliver these SNAs to the brain, the researchers turned to an unexpected route: the nose. Intranasal therapy has been investigated as a potential pathway for brain-targeted medications, but this is the first instance of nanoscale therapies utilizing this method to stimulate an immune response against brain cancers. “This is the first time that it has been shown that we can increase immune cell activation in glioblastoma tumors when we deliver nanoscale therapeutics from the nose to the brain,” Mahajan states.

Targeted Delivery and Immune Activation

The team confirmed the targeted delivery of the SNAs using a molecular tag visible under near-infrared light. The nanomedicine traveled along the path of the facial nerve, reaching the brain and concentrating the immune response within the tumor itself and associated lymph nodes. Importantly, the therapy showed minimal spread to other parts of the body, reducing the risk of unwanted side effects.

Further analysis revealed successful activation of the STING pathway and a bolstering of the immune system’s ability to combat the tumor. When combined with drugs that activate T lymphocytes, another crucial component of the immune system, the therapy eradicated tumors in the mice and induced long-term immunity, preventing recurrence. These results significantly surpassed those achieved with current STING-activating immunotherapies.

However, Stegh cautions that activating the STING pathway alone isn’t a cure. Glioblastoma tumors possess multiple mechanisms to suppress the immune response. His team is now focused on enhancing the SNAs to activate additional immune pathways, potentially tripling the therapeutic impact in a single treatment. What if we could unlock the full potential of the immune system to fight this devastating disease?

This research represents a significant step forward in the fight against glioblastoma, offering a safer and more effective treatment option. Could this non-invasive approach revolutionize brain cancer treatment as we know it?

Frequently Asked Questions About Nasal Drop Glioblastoma Treatment

• What is glioblastoma, and why is it so difficult to treat?

  Glioblastoma is an aggressive type of brain cancer that forms from astrocytes. Its difficulty lies in its rapid progression and the challenge of delivering effective treatments across the blood-brain barrier.

• How do spherical nucleic acids (SNAs) work in this treatment?

  SNAs are nanoscale structures that deliver tumor-fighting medication directly to the brain, activating the STING pathway and stimulating the immune system to attack the cancer cells.

• What is the STING pathway, and why is it important for cancer treatment?

  The STING pathway is a crucial immune response mechanism triggered by the detection of foreign DNA. Activating this pathway can help the body recognize and fight cancer cells.

• Is this nasal drop treatment currently available for patients?

  No, this treatment is currently in the preclinical stage, having only been tested on mice. Further research and clinical trials are needed before it can be made available to patients.

• What are the next steps in developing this treatment for human use?

  The next steps involve conducting clinical trials to assess the safety and efficacy of the treatment in humans, as well as optimizing the SNAs for even greater therapeutic impact.

• How does this treatment compare to existing glioblastoma therapies?

  This treatment offers a less invasive approach compared to current therapies that often require direct tumor injection. It also demonstrates improved immune activation and long-term tumor control in preclinical studies.